NTME — Netmed Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.55% | ||
| Return on Equity | -37.75% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 1997 | 1998 | 1999 | 2000 | 2001 | 2002E | 2003E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.89 | 0.4 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +54.5 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NetMed, Inc. has no business activities. During the fiscal year ended December 31, 2001, the Company's sole business activity, through its majority-owned subsidiary, OxyNet, Inc., involved research and development activities associated with a proprietary ceramic-based technology for separation of oxygen from ambient air and other gases. These activities were suspended effective December 31, 2001, pending efforts to locate a prospective licensee or development partner. The Company is continuing efforts, begun in 2001, to evaluate other business opportunities, which included preliminary investigation and due diligence. These efforts have not, in the judgment of the Company's management, produced an attractive merger or acquisition candidate. The Company is seeking a candidate with a proprietary product or service, which may be in the development stage, and offers an opportunity to realize these objectives.
Directors
- S. Trevor Ferger CEO (53)
- Kenneth Leachman VFN (54)
- Michael Blue DRC (55)
- Robert Massey DRC (62)
- Susan O'Toole DRC (59)
- Cecil Petitti DRC (54)
- Last Annual
- December 31st, 2001
- Last Interim
- June 30th, 2002
- Incorporated
- October 25th, 1989
- Public Since
- April 21st, 1999
- No. of Shareholders
- 417
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 13,713,597
- Address
- 1999 Bryan St Ste 900, DALLAS, 75201-3140
- Web
- Phone
- +1 6147939356
- Auditors
- Ernst & Young LLP
Similar to NTME
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:15 UTC, shares in Netmed are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Netmed last closed at $0.00 and the price had moved by +900% over the past 365 days. In terms of relative price strength the Netmed share price has outperformed the S&P500 Index by +759.66% over the past year.
There is no consensus recommendation for this security.
Netmed does not currently pay a dividend.
Netmed does not currently pay a dividend.
Netmed does not currently pay a dividend.
To buy shares in Netmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Netmed had a market capitalisation of .
Here are the trading details for Netmed:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NTME
Based on an overall assessment of its quality, value and momentum Netmed is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Netmed. Over the past six months, its share price has outperformed the S&P500 Index by +766.77%.
As of the last closing price of $0.00, shares in Netmed were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Netmed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Netmed's management team is headed by:
- S. Trevor Ferger - CEO
- Kenneth Leachman - VFN
- Michael Blue - DRC
- Robert Massey - DRC
- Susan O'Toole - DRC
- Cecil Petitti - DRC